Table IV. Time From Most Recent Increase in Dose of Step 1 (Blinded) Antihypertensive Medication Prior to Onset of Angioedema in ALLHAT Participants*.
Number (%) of Participants With Angioedema | |||||
---|---|---|---|---|---|
Time from Most Recent Step i Dose Increase to Onset of Angioedema | C | A | L | D | Total |
No dose increase† | 4 (50) | 0 | 20 (54) | 3 (60) | 27 (51) |
1–2 d | 0 | 0 | 0 | 0 | 0 |
3–7 d | 0 | 1 | 2 | 0 | 3 |
Total with dose increase within first week† | 0 | 1 (33) | 2 (5) | 0 | 3 (6) |
8–14 d | 0 | 0 | 2 | 0 | 2 |
15–30 d | 0 | 1 | 2 | 1 | 4 |
Total with dose increase within first month† | 0 | 2 (66) | 6 (16) | 1 (20) | 9 (17) |
31–60 d | 0 | 0 | 0 | 0 | 0 |
61–90 d | 0 | 0 | 1 | 0 | 1 |
Total with dose increase within first 3 months† | 0 | 2 (66) | 7 (19) | 1 (20) | 10 (19) |
91–182 d | 1 | 1 | 1 | 0 | 3 |
6 mo–1 yr | 1 | 0 | 4 | 1 | 6 |
ALLHAT indicates Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial; C, chlorthalidone; A, amlodipine; L, lisinopril; D, doxazosin. *For participants who experienced more than one episode of angioedema, only the first is considered. †Values are cumulative. |